CYNVEC, LLC
NEW YORK, NY · Founded 2004 · CIK 0001385095 · Biotech · Private
Sindbis virus-based immunotherapeutic vectors encoding tumor-associated antigens and immunomodulatory antibodies to activate T cells in cold tumors
cynvec.com →- Grants
- $4.4M
- 5 awards
- Sector median: 1
- Raised
- $500K
- 3 Form D · Aug 2017
- 110 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20082010201220142016201820202022
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $500,000 | |
| Private capital raised | Form D · SEC | $10,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · A Phase I Dose-escalation Study of Intraperitoneal CYN101 as Consolidation Immunotherapy in Women with Residual or Recurrent Ovarian Cancer Status after Chemotherapy | $995,814 | |
| Private capital raised | Form D · SEC | $15,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · A Phase I Dose-escalation Study of Intraperitoneal CYN101 as Consolidation Immunotherapy in Women with Residual or Recurrent Ovarian Cancer Status after Chemotherapy | $1,004,186 | |
| Federal grant | Department of Health and Human Services · Phase II · A novel and effective immunotherapeutic approach for tumors with a low mutational load and few tumor-infiltrating lymphocytes, such as ovarian cancer | $400,000 | |
| Federal grant | Department of Health and Human Services · Phase II · A novel and effective immunotherapeutic approach for tumors with a low mutational load and few tumor-infiltrating lymphocytes, such as ovarian cancer | $1,133,263 | |
| Federal grant | Department of Health and Human Services · Phase II · A novel and effective immunotherapeutic approach for tumors with a low mutational load and few tumor-infiltrating lymphocytes, such as ovarian cancer | $866,737 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1389 | NAWGEN, LLC | — | — |
| 1390 | VIVREON BIOSCIENCES LLC | — | — |
| 1391 | GROVE BIOPHARMA, INC. | — | — |
| 1392 | CYNVEC, LLC | — | $500K |
| 1393 | Infinite Elements, Inc. | — | — |
| 1394 | NEONC TECHNOLOGIES INC | — | $394K |
| 1395 | NOVO HEAL, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Steve BlumenthalDirector
- Steven BlumenthalDirector · Executive Officer
- Charles DoregoDirector
- Robert IvanhoeDirector
- Leonard LitwinDirector
- Carole PittelmanDirector
- Richard PurcellDirector · Executive Officer
- Frank StonebanksDirector · Executive Officer
- Daniel WildsExecutive Officer
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.